Allianz Asset Management
BTAI icon

Allianz Asset Management’s BioXcel Therapeutics BTAI Stock Holding History

Allianz Asset Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,112
Closed -$768K – 2396
2021
Q1 		$768K Buy
1,112
+577
+108% +$464K ﹤0.01% 1748
2020
Q4 		$396K Buy
+535
New +$417K ﹤0.01% 1680

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $5.54B AUM 44.68% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return

Allianz Asset Management's BTAI Position: Q2 2021 in Review

Allianz Asset Management sold out of BioXcel Therapeutics (BTAI) in Q2 2021, closing a stake of 1,112 shares — an estimated $768K sold.

Allianz Asset Management first reported a position in BTAI in Q4 2020 and held it in 2 quarters. The position peaked at $768K in Q1 2021. 108 funds tracked by Wall St. Rank hold BTAI as of Q2 2021.

  • Allianz Asset Management reported no remaining BioXcel Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Allianz Asset Management sold 1,112 BioXcel Therapeutics shares in Q2 2021, an estimated $768K.
  • Allianz Asset Management first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 2 quarters.
  • Allianz Asset Management's BioXcel Therapeutics position peaked at $768K in Q1 2021.
  • 108 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2021.

Based on Allianz Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.